Retatrutide has emerged as a new medication in the fight against obesity. This revolutionary drug, categorized as a dual GLP-1 and GIP receptor agonist, shows promising results in investigations. By activating these receptors, Retatrutide controls cravings, {promotesinsulin secretion, and ultimately